01509 232007 info@aureliabio.com

3-D Cell Biology

We have developed a 3-D micro-tissue system from electrospun material that can be used in conjunction with well plates for higher throughput screening. Additionally, we use Ultra Low Attachment (ULA) plates to generate and culture spheroids.

Phenotypic Screening

We specialise in physiologically relevant assays using cell-based formats in state of the art technologies. We have used a number of human primary cells in a number of assay formats.

WES: Western Assay System

The WesTM system from ProteinSimple is a fully automated device which runs the Simple Western size assay; a highly reproducible and sensitive alternative to standard Western blotting assays.

High Content Screening

High Content Screening (HCS) uses microscopic imaging to observe, measure and analyse multiple parameters within cells in a biological assay.

Label-Free Screening

Our scientists have in-depth experience of label-free technology applied to cell-based assays gained over the past 6 years using Corning Epic, PerkinElmer EnSpire and SRU Bioscience Bind instruments.


PROTAC (PROtein TArgeted Chimeric) is the ability to specifically degrade a protein using the endogenous machinery of the cell. We have developed assays for PROTAC using WES (ProteinSimple) and NanoLuc (Promega). 

Cell-Based Screening

Cell based assays are of key importance at a number of stages in the drug discovery process. Being able to examine the interaction between your target and compounds in a cellular context is of great advantage.

High Throughput Screening

With over 20 years of screening experience we are adept at designing screening assays and screening 100,000 to 1 million compounds in 384 well and 1536 well plates.

FLIPR Screening

We use FLIPR in a range of assay formats, readouts and target types.

Kinase Compound Profiling

Using Promega’s NanoBRET™ technology, we have employed intracellular kinase assays designed to study the interaction of compounds on kinase targets in intact living cells.

Cell Culture Services

Typical screens have required upwards of 1010 cells. We have developed methodologies to grow, sub-culture, harvest, cryopreserve and revive these quantities of cells from single batches, thus reducing screening variability, allowing cells to be used in an identical manner to other assay reagents, reviving and using what is required on a daily basis.

Flow Cytometry

Flow cytometry can simultaneously analyse multiple parameters such as relative size, internal complexity, relative fluorescence intensity, etc on the same cell within seconds. 

Protein-Protein Interactions

We have successfully used NanoBRET™ System (Promega) to detect protein- protein interactions in living cells.

Quantitative PCR

Using our Applied Biosystems™ QuantStudio™ 6 Flex Real-Time PCR system, we are able to investigate quantitative differences in mRNA expression in relation to pathways and targets identified as being of interest to clients. 

Biochemical Screening

We have carried out biochemical screening for a range of targets including but not limited to proteases, kinases, phosphodiesterase enzymes and protein:protein interactions.

Instrument and Reagent Validation

Acting as an intermediary between instrument manufacturers and reagent manufacturers and prospective clients, we can provide an expert lab-based environment for the validation of new technologies.

Hypoxia and Cancer

We have developed a physiologically relevant human cell-based assay to screen small molecules for their ability to inhibit adaptive responses to hypoxia.

Customised bioassay development, pharmacological profiling and compound screening

Aurelia Bioscience is a pre-clinical contract research organisation (CRO) specialising in bioassay development, pharmacological profiling and compound screening.

We work in early stages of the drug discovery pipeline including target identification and validation, hit identification, hit to lead as well as lead identification and optimisation. We have significant experience of different target classes and use cutting edge technologies to deliver client projects in a timely, efficient and cost-effective manner.

Conference: Oxford Global Discovery 2021

Aurelia Bioscience exhibited at Oxford Global: Discovery 2021 in Londonl, UK on 26th and 27th Novemvber. Additionally, our CEO, Dr. Gary Allenby gave a talk on PROTAC Assays: Successfully Measuring Protein Degradation.

Conference: ELRIG Drug Discovery 2021

Aurelia Bioscience exhibited and presented several posters at ELRIG Drug Discovery 2021, Liverpool on 19th and 20th October. Follow the link to view all our posters.

Vlog 5: FAQs

This is the 5th vlog of a 5-vlog series on 'How to develop effective in vitro assays for early drug discovery'. In this video, we have talked about some challenges you might face whilst developing your bioassay. For more insights, download our free e-book. Subscribe...

Video: 10 years of Drug Discovery

On our 10th anniversary, we are very excited to share with you all a short video capturing the very essence of our being, our commitment towards our clients, and most importantly, our passion for drug discovery: https://youtu.be/oenSPmUiwBo We would also like to take...

Vlog 4: Is your assay fit-for-purpose?

This is the 4th vlog of a 6-vlog series on 'How to develop effective in vitro assays for early drug discovery'. In this video, we have talked about the key guidelines and statistical rules you should follow to ensure your bioassays are reproducible and consistent. For...

Press Release: Charnwood Group Acquires Aurelia Bioscience

Dr. Gary Allenby and Kathy Dodgson, founders and directors of Aurelia Bioscience, are pleased to announce that after 10 years of success as a standalone biology contract research organisation, the company has been acquired by its collaborator- Charnwood Molecular. To...

Our PhD and pharma trained scientists have decades of experience in pre-clinical discovery, designing and developing low, medium and high throughput assays for hits-to-lead, lead identification and lead optimisation drug discovery phases

Are you looking for a CRO to help you discover your next breakthrough drug?